Pallak Agarwal, MD
Pulmonary Disease · Wyomissing, PANPI 1063766574
Payments from drug & device makers
Across 137 payments — averaging $28.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Intuitive Surgical$1K
- GSK$535
- AstraZeneca$483
- Regeneron Healthcare Solutions, Inc.$286
- Insmed, Inc.$221
- Sanofi$179
- plus $1K from 24 others
What the payments were for
- Travel & lodging$93024%
- Food & beverage$2,81473%
- Education$1003%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Intuitive Surgical | 8 | $1,002 |
| GSK | 25 | $535 |
| AstraZeneca(2 entities) | 19 | $483 |
| Regeneron Healthcare Solutions, Inc. | 7 | $286 |
| Insmed, Inc. | 11 | $221 |
| Sanofi | 8 | $179 |
| Genentech USA, Inc. | 7 | $119 |
| Sanofi-aventis U.S. LLC | 1 | $100 |
| Novartis | 5 | $97 |
| Axsome Therapeutics, Inc. | 5 | $78 |
| Amgen | 5 | $75 |
| United Therapeutics Corporation | 3 | $67 |
| Grifols USA, LLC | 4 | $64 |
| Mylan Specialty L.p. | 3 | $50 |
| Boehringer Ingelheim | 4 | $49 |
| Verona Pharma, Inc. | 2 | $49 |
| Merck | 3 | $49 |
| Sunovion Pharmaceuticals Inc. | 3 | $47 |
| Harmony Biosciences LLC | 2 | $44 |
| Viatris Specialty LLC | 1 | $35 |
| Actelion Pharmaceuticals US, Inc. | 2 | $34 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $33 |
| Ambu Inc. | 1 | $33 |
| Mallinckrodt Hospital Products Inc. | 1 | $22 |
| ARS Pharmaceuticals Operations, Inc. | 1 | $18 |
| Inspire Medical Systems, Inc. | 1 | $18 |
| Inari Medical, Inc. | 1 | $18 |
| Avadel CNS Pharmaceuticals, LLC | 1 | $15 |
| Teva Pharmaceuticals USA, Inc. | 1 | $12 |
| Johnson & Johnson | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Da Vinci Surgical System$892
- DUPIXENT$135
- NUCALA$125
- TEZSPIRE$115
How this compares
$3,844 in reported general payments places this provider in the 60th percentile of 703 pulmonary disease providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XolairOmalizumab | 130 | $600,740 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 318 | $311,555 |
| FasenraBenralizumab | 23 | $140,243 |
| Breo ElliptaFluticasone/Vilanterol | 145 | $94,730 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 63 | $68,145 |
| Spiriva RespimatTiotropium Bromide | 76 | $58,064 |
| Ambrisentan | 12 | $54,964 |
| Dupixent SyringeDupilumab | 15 | $54,489 |
| TezspireTezepelumab-Ekko | 11 | $46,930 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 40 | $39,632 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 118 | $25,357 |
| Incruse ElliptaUmeclidinium Bromide | 28 | $24,755 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 63 | $17,275 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 13 | $13,636 |
| DuleraMometasone/Formoterol | 28 | $13,425 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Incruse Ellipta, Arnuity Ellipta | $535 | $483,710557 claims |
| AstraZenecaFasenra, Breztri Aerosphere, Tezspire, Symbicort | $483 | $268,442142 claims |
| Boehringer IngelheimSpiriva Respimat, Stiolto Respimat | $49 | $71,70089 claims |
| MerckDulera | $49 | $13,42528 claims |
| Teva Pharmaceuticals USA, Inc.Qvar Redihaler | $12 | $9,15919 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 703 pulmonary disease providers in Pennsylvania.
Other pulmonary disease in Wyomissing
- Gerard CrinerPhiladelphia$18.2M
- Sandeep Bansaldu Bois$8.9M
- David WheelerPhiladelphia$7.7M
- Steven AlbeldaPhiladelphia$5.5M
- Paul SimonelliDanville$2.1M
- Kevin GibsonPittsburgh$1.3M
- Frank SciurbaPittsburgh$1.2M
- Joseph PilewskiPittsburgh$1M
- Steven DuncanPittsburgh$995K
- Tariq CheemaPittsburgh$907K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.